Mary Van Doren
Mary Van Doren, Executive Editorial Director at Dark Intelligence Group partner Mequoda Group, serves as DIG’s online editor. She optimizes DIG content for the Internet to ensure that it reaches the widest possible audience.
Mary’s experience includes writing search-optimized marketing copy both for Mequoda and for Mequoda clients, including the The Dark Intelligence Group, and directly tutoring clients in SEO content marketing. She has more than three decades of experience in both marketing and journalism. Just prior to joining Mequoda Group in 2012, she spent five years as Chief Copywriter for Elsevier Business Intelligence, where she helped promote publications, databases and conferences for C-suite executives in biopharma, medical devices and diagnostics.
Articles by Mary Van Doren
Combining Lean Techniques with Lab Automation to Get Impressive Results
From the Volume XXII No. 10 – July 13, 2015 Issue
PROBABLY NO AREA OF CLINICAL LABORATORY MEDICINE is experiencing the dramatic transformation happening in microbiol…
Medicare Ends Coverage for Some Pharmacogenomic Testing
From the Volume XXII NO. 9 – June 22, 2015 Issue
WHAT THE FEDERAL GOVERNMENT giveth with one hand, it will often taketh away with the other hand. It might be argued that this is true of federal support of pharmacogenomic testing — particularly for those tests clinical labor…
Some Labs Report Faster Pay For Molecular, Genetic Tests via New CPT Code Reimbursement Program
From the Volume XXII NO. 8 – June 1, 2015 Issue
DURING RECENT MONTHS, some labs are reporting improvement in how their claims for certain molecular and genetic tests are being reim…
New Laboratory Industry Trend: Labs Must Prepare for End of Fee-for-Service Model
From the Volume XXII NO. 7 – May 11, 2015 Issue
CEO SUMMARY: One stark difference between the presentations delivered at last year’s Executive War College and this year’s presentations in New Orleans last week was near-unanimous recognition that the era of fee-for-service payment is soon to end! Speaker after spea…
Theranos: Many Questions, but Very Few Answers
From the Volume XXII No. 6 – April 20, 2015 Issue
WHEN A COMPANY THAT GOES PUBLIC WITH ITS GOALS, regularly and repeatedly declaring its lofty ambitions to do good for mankind by disrupting the status quo and replacing it with something new and wonderful, it invites itself to be judged by its actions and what it actually delivers. Since Thera…
Top laboratory management requires top business skills
From the Volume XXII No. 5 – March 30, 2015 Issue
Every lab organization should aspire to achieve the attributes of Level Four: Use Benchmarks to Achieve Best-in-Class because this is the level of performance where the lab is delivering optimal clinical value at highest quality and lowest cost. This is an effort in which the business skills…
Early Experience with Accountable Care Organization Has Lessons for Pathologists
From the Volume XXII No. 4 – March 9, 2015 Issue
More than 500 accountable care organizations now operate nationwide. To date, however, few independent pathology groups and clinical labs have successfully negotiated lab testing contracts with these ACO…
Protecting Access to Medicare Act of 2014 Could Harm Independent Community Labs
From the Volume XXII No. 3 – February 17, 2015 Issue
In the Protecting Access to Medicare Act of 2014 (PAMA), the Center for Medicare and Medicaid Services (CMA) is directed to collect market price data and use the data to establish prices for the Medicare Part B Clinical Laborato…
UCLA Pathologists, Radiologists Produce Integrated Diagnostic Lab Reports
From the Volume XXII No. 2 – January 26, 2015 Issue
CEO SUMMARY: To simplify diagnostic lab reporting, the pathology and radiology departments at the David Geffen School of Medicine/UCLA Medical Center are working together to deliver integrated diagnostic information to treating oncologists. This innovative strategy is designed to…
Healthcare Cost Solutions Will Continue to Pinch Lab Industry Revenues in 2015
From the Volume XXII No. 1 – January 5, 2015 Issue
CEO SUMMARY: Will 2015 turn out to be a watershed year for the clinical laboratory industry? With healthcare cost solutions continuing to squeeze laboratory profits, two federal agencies are pushing forw…
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized